GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Gross Margin %

Syncom Formulation (India) (NSE:SYNCOMF) Gross Margin % : 39.32% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Syncom Formulation (India)'s Gross Profit for the three months ended in Dec. 2023 was ₹256 Mil. Syncom Formulation (India)'s Revenue for the three months ended in Dec. 2023 was ₹651 Mil. Therefore, Syncom Formulation (India)'s Gross Margin % for the quarter that ended in Dec. 2023 was 39.32%.


The historical rank and industry rank for Syncom Formulation (India)'s Gross Margin % or its related term are showing as below:

NSE:SYNCOMF' s Gross Margin % Range Over the Past 10 Years
Min: 21.41   Med: 28.21   Max: 35.61
Current: 35.61


During the past 13 years, the highest Gross Margin % of Syncom Formulation (India) was 35.61%. The lowest was 21.41%. And the median was 28.21%.

NSE:SYNCOMF's Gross Margin % is ranked worse than
69.83% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.47 vs NSE:SYNCOMF: 35.61

Syncom Formulation (India) had a gross margin of 39.32% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Syncom Formulation (India) was 7.60% per year.


Syncom Formulation (India) Gross Margin % Historical Data

The historical data trend for Syncom Formulation (India)'s Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Gross Margin % Chart

Syncom Formulation (India) Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.46 21.41 30.19 32.58 32.65

Syncom Formulation (India) Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.40 23.12 40.59 38.75 39.32

Competitive Comparison of Syncom Formulation (India)'s Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Gross Margin % distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Gross Margin % falls into.



Syncom Formulation (India) Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Syncom Formulation (India)'s Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=726.4 / 2224.861
=(Revenue - Cost of Goods Sold) / Revenue
=(2224.861 - 1498.486) / 2224.861
=32.65 %

Syncom Formulation (India)'s Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=256.1 / 651.395
=(Revenue - Cost of Goods Sold) / Revenue
=(651.395 - 395.287) / 651.395
=39.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Syncom Formulation (India)  (NSE:SYNCOMF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Syncom Formulation (India) had a gross margin of 39.32% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Syncom Formulation (India) Gross Margin % Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines